Hologic, Inc. $HOLX is Nuance Investments LLC’s 2nd Largest Position

Nuance Investments LLC lifted its position in Hologic, Inc. (NASDAQ:HOLX) by 27.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,378,859 shares of the medical equipment provider’s stock after purchasing an additional 297,526 shares during the quarter. Hologic comprises approximately 7.0% of Nuance Investments LLC’s portfolio, making the stock its 2nd largest holding. Nuance Investments LLC’s holdings in Hologic were worth $89,846,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Victory Capital Management Inc. increased its stake in Hologic by 34.4% in the 1st quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider’s stock worth $408,283,000 after acquiring an additional 1,692,177 shares during the last quarter. Invesco Ltd. boosted its position in shares of Hologic by 18.8% during the 1st quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider’s stock valued at $298,655,000 after acquiring an additional 764,573 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of Hologic by 1.6% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,473,098 shares of the medical equipment provider’s stock worth $276,303,000 after purchasing an additional 69,878 shares in the last quarter. Ameriprise Financial Inc. increased its position in shares of Hologic by 0.8% in the first quarter. Ameriprise Financial Inc. now owns 3,512,594 shares of the medical equipment provider’s stock worth $216,973,000 after purchasing an additional 29,133 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in Hologic by 8.1% in the first quarter. Dimensional Fund Advisors LP now owns 2,838,656 shares of the medical equipment provider’s stock valued at $175,331,000 after purchasing an additional 213,366 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on HOLX. Raymond James Financial cut shares of Hologic from a “moderate buy” rating to a “hold” rating in a research note on Wednesday, October 22nd. Royal Bank Of Canada upgraded shares of Hologic from a “sector perform” rating to an “outperform” rating and upped their target price for the stock from $72.00 to $87.00 in a research report on Wednesday, August 6th. BTIG Research restated a “neutral” rating on shares of Hologic in a research report on Tuesday, October 21st. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $78.00 price target on shares of Hologic in a research note on Wednesday, October 22nd. Finally, Evercore ISI set a $78.00 price objective on Hologic and gave the stock an “outperform” rating in a report on Tuesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and thirteen have assigned a Hold rating to the company. According to data from MarketBeat, Hologic currently has an average rating of “Hold” and an average price target of $79.23.

Hologic Stock Performance

Hologic stock opened at $74.10 on Friday. The firm has a fifty day simple moving average of $68.99 and a two-hundred day simple moving average of $65.16. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $80.31. The company has a market capitalization of $16.48 billion, a PE ratio of 30.75, a P/E/G ratio of 2.54 and a beta of 0.65.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.03. The firm had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.03 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period last year, the firm earned $1.01 earnings per share. Research analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Insider Activity at Hologic

In other news, CEO Stephen P. Macmillan sold 138,358 shares of the firm’s stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total value of $9,265,835.26. Following the transaction, the chief executive officer owned 1,234,624 shares in the company, valued at approximately $82,682,769.28. This trade represents a 10.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Christiana Stamoulis sold 7,402 shares of the company’s stock in a transaction on Monday, October 20th. The shares were sold at an average price of $73.07, for a total transaction of $540,864.14. Following the sale, the director owned 47,336 shares of the company’s stock, valued at $3,458,841.52. This represents a 13.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 1.88% of the stock is owned by company insiders.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.